X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DIVIS LABORATORIES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DIVIS LABORATORIES LUPIN LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 27.7 32.3 85.9% View Chart
P/BV x 2.9 5.8 50.2% View Chart
Dividend Yield % 0.6 0.9 66.8%  

Financials

 LUPIN LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
DIVIS LABORATORIES
Mar-17
LUPIN LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,4651,222 119.9%   
Low Rs727784 92.7%   
Sales per share (Unadj.) Rs349.6153.1 228.3%  
Earnings per share (Unadj.) Rs5.639.9 13.9%  
Cash flow per share (Unadj.) Rs29.644.6 66.3%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.51.0 45.8%  
Book value per share (Unadj.) Rs300.3201.8 148.8%  
Shares outstanding (eoy) m452.08265.47 170.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.16.6 47.9%   
Avg P/E ratio x197.225.1 785.4%  
P/CF ratio (eoy) x37.122.5 164.7%  
Price / Book Value ratio x3.65.0 73.4%  
Dividend payout %90.025.0 359.4%   
Avg Mkt Cap Rs m495,502266,266 186.1%   
No. of employees `00017.09.7 175.1%   
Total wages/salary Rs m28,6474,687 611.2%   
Avg. sales/employee Rs Th9,273.64,175.0 222.1%   
Avg. wages/employee Rs Th1,681.0481.5 349.1%   
Avg. net profit/employee Rs Th147.41,089.3 13.5%   
INCOME DATA
Net Sales Rs m158,04240,643 388.8%  
Other income Rs m1,504749 200.8%   
Total revenues Rs m159,54541,392 385.4%   
Gross profit Rs m31,47514,460 217.7%  
Depreciation Rs m10,8591,233 880.5%   
Interest Rs m2,04423 9,042.0%   
Profit before tax Rs m20,07613,953 143.9%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,8853,349 86.1%   
Profit after tax Rs m2,51310,604 23.7%  
Gross profit margin %19.935.6 56.0%  
Effective tax rate %14.424.0 59.9%   
Net profit margin %1.626.1 6.1%  
BALANCE SHEET DATA
Current assets Rs m122,09540,105 304.4%   
Current liabilities Rs m50,9566,595 772.7%   
Net working cap to sales %45.082.5 54.6%  
Current ratio x2.46.1 39.4%  
Inventory Days Days85119 71.4%  
Debtors Days Days12081 148.6%  
Net fixed assets Rs m129,87619,995 649.5%   
Share capital Rs m904531 170.3%   
"Free" reserves Rs m134,86653,043 254.3%   
Net worth Rs m135,77153,574 253.4%   
Long term debt Rs m64,2450-   
Total assets Rs m263,05461,585 427.1%  
Interest coverage x10.8618.4 1.8%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.7 91.0%   
Return on assets %1.717.3 10.0%  
Return on equity %1.919.8 9.3%  
Return on capital %3.726.1 14.3%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m53,14135,384 150.2%   
Fx outflow Rs m19,33510,399 185.9%   
Net fx Rs m33,80724,985 135.3%   
CASH FLOW
From Operations Rs m17,51211,493 152.4%  
From Investments Rs m-14,073-11,372 123.8%  
From Financial Activity Rs m-14,921-93 16,026.7%  
Net Cashflow Rs m-11,48228 -40,428.5%  

Share Holding

Indian Promoters % 46.6 52.0 89.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 31.9 19.0 167.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.2 58.7%  
Shareholders   98,259 31,796 309.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 220 Points Higher; Metal & Realty Stocks Gain the Most(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.5% while the Hang Seng is up 0.5%.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 17, 2018 11:29 AM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - NOVARTIS COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS